Replies to post #6748 on Vericel Corp. (VCEL)

[lasers]

No doubt the Insitutionals were the buyers. They would be buying based on $VCEL combined projected earnings for Epicel and Maci!

the tutes held this up and are accumulating

IMO as was stated previously $VCEL has been looking for a Partner to support ixcell DCM.

In the 2Q2017 $VCEL Earning were -$0.07 and beat all analysts estimates of -$0.20. The 3Q2017 earnings will be posted Nov 10, 2017 and all analysts combined estimates are for -$0.16. With no clinical trials the R&D costs are significantly reduced and $VCEL 3Q2017 EPS will IMO approach that of 2Q2017.

China's ICT looms as a possible Partner for $VCEL's ixcell DCM

http://investors.vcel.com/releasedetail.cfm?ReleaseID=1025740

Vericel Corporation (Nasdaq:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that it has entered into a License Agreement with Innovative Cellular Therapeutics (ICT), a leading China-based cell therapy company and developer of CAR-T cell therapy for cancer treatment, for development, manufacturing and commercialization of the Vericel product portfolio. Under the terms of the agreement, ICT will acquire exclusive rights to develop and distribute Carticel®, MACI®, Ixmyelocel-T, and Epicel® in Greater China, South Korea, Singapore, and other countries in the region. In connection with the license agreement, ICT will also enter in a warrant agreement with Vericel.